Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Open-label, Multicenter Study to Evaluate Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn's Disease Patients

NCT06408935 is registered in ClinicalTrials.gov with Janssen-Cilag Ltd. as lead sponsor.

NCT NCT06408935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06408935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Open-label, Multicenter Study to Evaluate Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn's Disease Patients
Lead sponsor
Janssen-Cilag Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 17, 2024
Completion date
March 6, 2028
Enrollment
120 (actual)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease